hsa-miR-21-5p miREIA (Cat. No: RDM0001H)hsa-miR-21-5p is a typical onco-miRNA frequently upregulated in solid tumors, most of the targets are tumor suppressors. Pancreatic, colorectal, gastric, brain, breast, lung, esophageal and hepatocellular cancers were often associated with miR-21-5p. It also plays role in the development of cardiovascular disease, acute myocardial infarction, pulmonary diseases and in regulation of immunological and developmental processes. Besides in tissues, recent evidence indicates the presence of miR-21-5p in various types of extracellular fluid, such as plasma, serum, CSF, saliva, gastric juice, pancreatic juice, sputum, and pancreatic cyst fluid.
Click to see the product brochure hsa-miR-21-5p miREIA kit
hsa-miR-93-5p miREIA (Cat. No: RDM0002H)
hsa-miR-93-5p is an onco-miRNA. Up-regulation of miR-93-5p is correlated with worse clinic-pathological features and can serve as an independent marker for poor prognosis in patients with non-small cell lung cancer. NSCLC cell proliferation, migration, and invasion were significantly stimulated by miR-93-5p upregulation and inhibited by miR-93-5p downregulation. miR-93-5p was also up-regulated in non-muscle invasive bladder cancer.Increased expression of circulating miR-93-5p in women with polycystic ovary syndrome may represent a novel non-invasive biomarker for diagnosis.
hsa-miR-145-5p miREIA (Cat. No: RDM0003H)
hsa-miR-145-5p might constitute a promising molecular marker for renal cell carcinoma classification and staging. It was described as a prognostic biomarker of overall survival in colon cancer but as a tumor suppressor gene in NSCLC metastasis.Low expression and plasma levels were found in patients with coronary artery disease and acute myocardial infarction.
hsa-miR-150-5p miREIA (Cat. No: RDM0004H)
hsa-miR-150-5p is linked with number of cancers. It was up-regulated in plasma of melanoma patients. Findings also demonstrate miR-150-5p as a putative novel biomarker of inflammatory active disease with the potential to be used for early diagnosis of multiple sclerosis. miR-150-5p is downregulated in children with tuberculosis. In aplastic anemia, levels of miR-150-5p were elevated, compared to healthy controls.miR-150-5p is expressed in the lymph nodes, spleen and thymus and it is highly up-regulated during lymphocyte maturation and down-regulated during the activation of mature B and T cells. In vivo studies show that miR-150 is released in the external environment after T cell activation and this may cause an increase of its blood levels during immune system stimulation.
hsa-miR-191-5p miREIA (Cat. No: RDM0005H)
hsa-miR-191-5p is dysregulated in many types of cancers (>20) and various other diseases like T2DM, pulmonary hypertension, Crohn’s and Alzheimer’s diseases. miR-191-5p regulates important cellular processes such as cell proliferation, differentiation and apoptosis. miR-191-5p is a promising disease biomarker and therapeutic target.
hsa-miR-451a miREIA (Cat. No.: RDM0006H)
hsa-miR-451a-5p levels are differentially expressed in patients with nonalcoholic fatty liver disease, rheumatoid arthritis, diabetes and several types of cancer including renal cell carcinoma, nonsmall lung cancer, osteosarcoma, esophageal adenocarcinoma and epithelial ovarian cancer. It is overexpressed in endometriotic lesion tissue and is also associated with endometriotic lesion survival.miR-451a-5p is expressed in the circulation, predominantly by erythrocytes, where i tis proposed to play a role in the differentiation and/or maturation of red blood cells.
- hsa-miR-15a-5p miREIA (Cat. No: RDM0007H)
- hsa-miR-16-5p miREIA (Cat. No: RDM0008H)
- hsa-miR-23a-3p miREIA (Cat. No: RDM0009H)
- hsa-miR-197-3p miREIA (Cat. No: RDM0010H)
- hsa-miR-320a miREIA (Cat. No: RDM0011H)
- hsa-miR-24-3p miREIA (Cat. No: RDM0012H)
- hsa-miR-142-5p miREIA (Cat. No: RDM0013H)
- hsa-miR-222-3p miREIA (Cat. No: RDM0014H)
- hsa-miR-223-3p miREIA (Cat. No: RDM0015H)
- hsa-miR-499a-5p miREIA (Cat. No: RDM0016H)